<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://endo.endojournals.org">
<title>Endocrinology Current Issue</title>
<link>http://endo.endojournals.org</link>
<description>Endocrinology RSS feed -- current issue</description>
<prism:coverDisplayDate>Nov  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Endocrinology</prism:publicationName>
<prism:issn>0013-7227</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/4819?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4823?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4835?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4846?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4855?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4863?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4874?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4883?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4892?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4901?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4911?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4920?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4931?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4941?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4950?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4958?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4968?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4977?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4989?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/4999?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5010?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5016?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5027?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5036?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5046?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5055?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5065?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5074?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5085?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5094?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5106?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5113?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5119?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5125?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5135?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5143?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5153?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5163?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5171?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/content/abstract/150/11/5181?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/5191?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/5191-a?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/5192?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/5192-a?rss=1" />
  <rdf:li rdf:resource="http://endo.endojournals.org/cgi/reprint/150/11/5193?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://endo.endojournals.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://endo.endojournals.org/icons/banner/title.gif">
<title>Endocrinology</title>
<url>http://endo.endojournals.org/icons/banner/title.gif</url>
<link>http://endo.endojournals.org</link>
</image>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/4819?rss=1">
<title><![CDATA[Does Finger Fat Produce Sex Differences in Second to Fourth Digit Ratios?]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/4819?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Wallen, K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0986</dc:identifier>
<dc:title><![CDATA[Does Finger Fat Produce Sex Differences in Second to Fourth Digit Ratios?]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4822</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4819</prism:startingPage>
<prism:section>NEWS AND VIEWS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4823?rss=1">
<title><![CDATA[Accelerated Cartilage Resorption by Chondroclasts during Bone Fracture Healing in Osteoprotegerin-Deficient Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4823?rss=1</link>
<description><![CDATA[
<p>Receptor activator of nuclear factor-B ligand (RANKL) and osteoprotegerin (OPG), a decoy receptor of RANKL, maintain bone mass by regulating the differentiation of osteoclasts, which are bone-resorbing cells. Endochondral bone ossification and bone fracture healing involve cartilage resorption, a less well-understood process that is needed for replacement of cartilage by bone. Here we describe the role of OPG produced by chondrocytes in chondroclastogenesis. Fracture healing in OPG<sup>&ndash;/&ndash;</sup> mice showed faster union of the fractured bone, faster resorption of the cartilaginous callus, and an increased number of chondroclasts at the chondroosseous junctions compared with that in wild-type littermates. When a cultured pellet of OPG<sup>&ndash;/&ndash;</sup> chondrocytes was transplanted beneath the kidney capsule, the pellet recruited many chondroclasts. The pellet showed the ability to induce tartrate-resistant acid phosphatase-positive multinucleated cells from RAW 264.7 cells <I>in vitro</I>. Finally, OPG<sup>&ndash;/&ndash;</sup> chondrocytes (but not wild-type chondrocytes) cultured with spleen cells induced many tartrate-resistant acid phosphatase-positive multinucleated cells. The expression of RANKL and OPG in chondrocytes was regulated by several osteotropic factors including 1,25-dihydroxyvitamin D<SUB>3</SUB>, PTHrP, IL-1, and TNF-. Thus, local OPG produced by chondrocytes probably controls cartilage resorption as a negative regulator for chondrocyte-dependent chondroclastogenesis.</p>
]]></description>
<dc:creator><![CDATA[Ota, N., Takaishi, H., Kosaki, N., Takito, J., Yoda, M., Tohmonda, T., Kimura, T., Okada, Y., Yasuda, H., Kawaguchi, H., Matsumoto, M., Chiba, K., Ikegami, H., Toyama, Y.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0452</dc:identifier>
<dc:title><![CDATA[Accelerated Cartilage Resorption by Chondroclasts during Bone Fracture Healing in Osteoprotegerin-Deficient Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4834</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4823</prism:startingPage>
<prism:section>CALCIUM-REGULATING HORMONES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4835?rss=1">
<title><![CDATA[Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4835?rss=1</link>
<description><![CDATA[
<p>We examined the role of bone remodeling in the regulation of circulating concentrations of FGF23 using mouse models manifesting differing degrees of coupled and uncoupled bone turnover. Administration of the antiresorptive agent osteoprotegerin produced a profound reduction in bone resorption and formation in male and oophorectomized female mice, accompanied by an increase in serum levels of fibroblast growth factor 23 (FGF23) and a reduction in circulating 1,25-dihydroxyvitamin D [1,25(OH)<SUB>2</SUB>D]. In contrast, exogenous PTH(1-34) administration increased bone turnover and reduced circulating FGF23. In 1,25(OH)<SUB>2</SUB>D-deficient, 25-hydroxyvitamin D 1-hydroxylase null mice on a high-calcium diet, endogenous PTH was elevated, bone formation but not resorption was increased, and serum FGF23 was virtually undetectable; on a rescue diet, serum calcium was normalized, PTH levels were reduced, bone formation was reduced, and serum FGF23 levels increased. After PTH treatment of wild-type mice, gene expression of dentin matrix protein 1 (DMP1) in bone was increased, whereas gene expression of FGF23 was reduced. <I>In vitro</I> studies in the osteoblastic cell line UMR-106 showed that externally added DMP1 could inhibit FGF23 gene expression and production stimulated by 1,25(OH)<SUB>2</SUB>D<SUB>3</SUB>. The results show that osteoblastic bone formation is a potent modulator of FGF23 production and release into the circulation, suggest that the biological consequences on mineral homeostasis of circulating FGF23 may also be dependent on the prevailing rate of bone turnover, and provide evidence that DMP1 may be a direct negative regulator of FGF23 production in osteoblastic cells.</p>
]]></description>
<dc:creator><![CDATA[Samadfam, R., Richard, C., Nguyen-Yamamoto, L., Bolivar, I., Goltzman, D.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0472</dc:identifier>
<dc:title><![CDATA[Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4845</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4835</prism:startingPage>
<prism:section>CALCIUM-REGULATING HORMONES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4846?rss=1">
<title><![CDATA[Progesterone Receptor Membrane Component-1 Regulates the Development and Cisplatin Sensitivity of Human Ovarian Tumors in Athymic Nude Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4846?rss=1</link>
<description><![CDATA[
<p>To determine whether progesterone receptor membrane component 1 (PGRMC1) regulates the development and cisplatin (CDDP)-sensitivity of human ovarian tumors, PGRMC1 was depleted from a human ovarian cancer cell line, dsRed-SKOV-3 cells, using a short hairpin RNA knockdown approach. Compared with parental dsRed-SKOV-3 cells, the PGRMC1-deplete cells grew slower <I>in vitro</I> and did not show progesterone&rsquo;s (P4) antiapoptotic effect. In fact, P4 induced apoptosis in PGRMC1-deplete cells in a dose-dependent manner. When transplanted into the peritoneum of athymic nude mice, parental dsRed-SKOV-3 cells developed numerous tumors, which were classified as either typical or oxyphilic clear cell tumors. CDDP increased the percentage of apoptotic nuclei in typical clear cell tumors and P4 attenuated CDDP-induced apoptosis. In contrast, the percentage of apoptotic nuclei in oxyphilic clear cell tumors was low (&le;1%) and was not significantly affected by CDDP and/or P4. Compared with tumors derived from parental dsRed SKOV-3 cells, PGRMC1-deplete tumors: 1) developed in fewer mice, 2) formed less frequently, 3) appeared smaller, and 4) resulted in fewer oxyphilic clear cell tumors. These PGRMC1-deplete tumors were not responsive to CDDP&rsquo;s apoptotic effects. The failure to respond to CDDP could be due to their poorly developed microvasculature system as judged by percentage of CD31-stained endothelial cells and/or their increased expression of ATP-binding cassette transporters, which are involved in drug resistance. Taken together, these findings indicate that PGRMC1 plays an essential role in the development and CDDP sensitivity of human ovarian tumors.</p>
]]></description>
<dc:creator><![CDATA[Peluso, J. J., Gawkowska, A., Liu, X., Shioda, T., Pru, J. K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0730</dc:identifier>
<dc:title><![CDATA[Progesterone Receptor Membrane Component-1 Regulates the Development and Cisplatin Sensitivity of Human Ovarian Tumors in Athymic Nude Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4854</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4846</prism:startingPage>
<prism:section>CANCER-ONCOGENES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4855?rss=1">
<title><![CDATA[{beta}-Cell-Specific Overexpression of Glutathione Peroxidase Preserves Intranuclear MafA and Reverses Diabetes in db/db Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4855?rss=1</link>
<description><![CDATA[
<p>Chronic hyperglycemia causes oxidative stress, which contributes to damage in various tissues and cells, including pancreatic &beta;-cells. The expression levels of antioxidant enzymes in the islet are low compared with other tissues, rendering the &beta;-cell more susceptible to damage caused by hyperglycemia. The aim of this study was to investigate whether increasing levels of endogenous glutathione peroxidase-1 (GPx-1), specifically in &beta;-cells, can protect them against the adverse effects of chronic hyperglycemia and assess mechanisms that may be involved. C57BLKS/J mice overexpressing the antioxidant enzyme GPx-1 only in pancreatic &beta;-cells were generated. The biological effectiveness of the overexpressed GPx-1 transgene was documented when &beta;-cells of transgenic mice were protected from streptozotocin. The transgene was then introgressed into the &beta;-cells of <I>db/db</I> mice. Without use of hypoglycemic agents, hyperglycemia in <I>db/db-</I>GPx(+) mice was initially ameliorated compared with <I>db/db</I>-GPx(&ndash;) animals and then substantially reversed by 20 wk of age. &beta;-Cell volume and insulin granulation and immunostaining were greater in <I>db/db</I>-GPx(+) animals compared with <I>db/db</I>-GPx(&ndash;) animals. Importantly, the loss of intranuclear musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) that was observed in nontransgenic <I>db/db</I> mice was prevented by GPx-1 overexpression, making this a likely mechanism for the improved glycemic control. These studies demonstrate that enhancement of intrinsic antioxidant defenses of the &beta;-cell protects it against deterioration during hyperglycemia.</p>
]]></description>
<dc:creator><![CDATA[Harmon, J. S., Bogdani, M., Parazzoli, S. D., Mak, S. S. M., Oseid, E. A., Berghmans, M., LeBoeuf, R. C., Robertson, R. P.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0708</dc:identifier>
<dc:title><![CDATA[{beta}-Cell-Specific Overexpression of Glutathione Peroxidase Preserves Intranuclear MafA and Reverses Diabetes in db/db Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4862</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4855</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4863?rss=1">
<title><![CDATA[Gene Therapy with Neurogenin 3 and Betacellulin Reverses Major Metabolic Problems in Insulin-Deficient Diabetic Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4863?rss=1</link>
<description><![CDATA[
<p>Insulin deficiency in type 1 diabetes leads to disruptions in glucose, lipid, and ketone metabolism with resultant hyperglycemia, hyperlipidemia, and ketonemia. Exogenous insulin and hepatic insulin gene therapy cannot mimic the robust glucose-stimulated insulin secretion (GSIS) from native pancreatic islets. Gene therapy of streptozotocin-diabetic mice with neurogenin 3 (Ngn3) and betacellulin (Btc) leads to the induction of periportal oval cell-derived neo-islets that exhibit GSIS. We hence hypothesized that this gene therapy regimen may lead to a complete correction of the glucose and lipid metabolic abnormalities associated with insulin deficiency; we further hypothesized that the neo-islets formed in response to Ngn3-Btc gene delivery may display an ultrastructure and transcription profile similar to that of pancreatic islets. We injected streptozotocin-diabetic mice with helper-dependent adenoviral vectors carrying Ngn3 and Btc, which restored GSIS and reversed hyperglycemia in these animals. The treatment also normalized hepatic glucose secretion and reversed ketonemia. Furthermore, it restored hepatic glycogen content and reinstated hepatic lipogenesis-related gene transcripts back to nondiabetic levels. By transmission electron microscopy, the neo-islets displayed electron-dense granules that were similar in appearance to those in pancreatic islets. Finally, using RNA obtained by laser capture microdissection of the periportal neo-islets and normal pancreatic islets, we found that the neo-islets and pancreatic islets exhibited a very similar transcription profile on microarray-based transcriptome analysis. Taken together, this indicates that Ngn3-Btc gene therapy corrects the underlying dysregulated glucose and lipid metabolism in insulin-deficient diabetic mice by inducing neo-islets in the liver that are similar to pancreatic islets in structure and gene expression profile.</p>
]]></description>
<dc:creator><![CDATA[Yechoor, V., Liu, V., Paul, A., Lee, J., Buras, E., Ozer, K., Samson, S., Chan, L.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:subject><![CDATA[Endocrinology, Endocrinology]]></dc:subject>
<dc:identifier>info:doi/10.1210/en.2009-0527</dc:identifier>
<dc:title><![CDATA[Gene Therapy with Neurogenin 3 and Betacellulin Reverses Major Metabolic Problems in Insulin-Deficient Diabetic Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4873</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4863</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4874?rss=1">
<title><![CDATA[Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4874?rss=1</link>
<description><![CDATA[
<p>Recent studies demonstrated a role for hypothalamic insulin and leptin action in the regulation of glucose homeostasis. This regulation involves proopiomelanocortin (POMC) neurons because suppression of phosphatidyl inositol 3-kinase (PI3K) signaling in these neurons blunts the acute effects of insulin and leptin on POMC neuronal activity. In the current study, we investigated whether disruption of PI3K signaling in POMC neurons alters normal glucose homeostasis using mouse models designed to both increase and decrease PI3K-mediated signaling in these neurons. We found that deleting p85 alone induced resistance to diet-induced obesity. In contrast, deletion of the p110 catalytic subunit of PI3K led to increased weight gain and adipose tissue along with reduced energy expenditure. Independent of these effects, increased PI3K activity in POMC neurons improved insulin sensitivity, whereas decreased PI3K signaling resulted in impaired glucose regulation. These studies show that activity of the PI3K pathway in POMC neurons is involved in not only normal energy regulation but also glucose homeostasis.</p>
]]></description>
<dc:creator><![CDATA[Hill, J. W., Xu, Y., Preitner, F., Fukuda, M., Cho, Y.-R., Luo, J., Balthasar, N., Coppari, R., Cantley, L. C., Kahn, B. B., Zhao, J. J., Elmquist, J. K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0454</dc:identifier>
<dc:title><![CDATA[Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4882</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4874</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4883?rss=1">
<title><![CDATA[Impaired Skeletal Muscle {beta}-Adrenergic Activation and Lipolysis Are Associated with Whole-Body Insulin Resistance in Rats Bred for Low Intrinsic Exercise Capacity]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4883?rss=1</link>
<description><![CDATA[
<p>Rats selectively bred for high endurance running capacity (HCR) have higher insulin sensitivity and improved metabolic health compared with those bred for low endurance capacity (LCR). We investigated several skeletal muscle characteristics, <I>in vitro</I> and <I>in vivo</I>, that could contribute to the metabolic phenotypes observed in sedentary LCR and HCR rats. After 16 generations of selective breeding, HCR had approximately 400% higher running capacity (<I>P</I> &lt; 0.001), improved insulin sensitivity (<I>P</I> &lt; 0.001), and lower fasting plasma glucose and triglycerides (<I>P</I> &lt; 0.05) compared with LCR. Skeletal muscle ceramide and diacylglycerol content, basal AMP-activated protein kinase (AMPK) activity, and basal lipolysis were similar between LCR and HCR. However, the stimulation of lipolysis in response to 10 &micro;<scp>m</scp> isoproterenol was 70% higher in HCR (<I>P</I> = 0.004). Impaired isoproterenol sensitivity in LCR was associated with lower basal triacylglycerol lipase activity, Ser660 phosphorylation of HSL, and &beta;2-adrenergic receptor protein content in skeletal muscle. Expression of the orphan nuclear receptor Nur77, which is induced by &beta;-adrenergic signaling and is associated with insulin sensitivity, was lower in LCR (<I>P</I> &lt; 0.05). Muscle protein content of Nur77 target genes, including uncoupling protein 3, fatty acid translocase/CD36, and the AMPK 3 subunit were also lower in LCR (<I>P</I> &lt; 0.05). Our investigation associates whole-body insulin resistance with impaired &beta;-adrenergic response and reduced expression of genes that are critical regulators of glucose and lipid metabolism in skeletal muscle. We identify impaired &beta;-adrenergic signal transduction as a potential mechanism for impaired metabolic health after artificial selection for low intrinsic exercise capacity.</p>
]]></description>
<dc:creator><![CDATA[Lessard, S. J., Rivas, D. A., Chen, Z.-P., van Denderen, B. J., Watt, M. J., Koch, L. G., Britton, S. L., Kemp, B. E., Hawley, J. A.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0158</dc:identifier>
<dc:title><![CDATA[Impaired Skeletal Muscle {beta}-Adrenergic Activation and Lipolysis Are Associated with Whole-Body Insulin Resistance in Rats Bred for Low Intrinsic Exercise Capacity]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4891</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4883</prism:startingPage>
<prism:section>DIABETES-INSULIN-GLUCAGON-GASTROINTESTINAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4892?rss=1">
<title><![CDATA[Short-Term Regulation of Tumor Necrosis Factor-{alpha}-Induced Lipolysis in 3T3-L1 Adipocytes Is Mediated through the Inducible Nitric Oxide Synthase/Nitric Oxide-Dependent Pathway]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4892?rss=1</link>
<description><![CDATA[
<p>TNF- has several effects on adipocytes that may be related to the development of type 2 diabetes in obese subjects. Many studies demonstrated that long-term treatment with TNF- increases lipolysis in adipocytes. However, the short-term (&lt;4 h) effects of TNF- on lipolysis have not been well investigated. The aim of this study was to investigate the short-term regulatory mechanism of TNF--induced lipolysis in 3T3-L1 adipocytes. Well-differentiated 3T3-L1 adipocytes were used. Lipolysis was determined by measuring glycerol release. Expression of inducible nitric oxide (iNOS) and nitric oxide (NO) production were measured, respectively, by Western blots and the Griess reagent. A selective iNOS inhibitor (s-ethylisothiourea &middot; HBr), an adenylyl cyclase inhibitor (SQ22536), and a guanylyl cyclase inhibitor (LY83583) were used to investigate the involvement of iNOS, cAMP, and cGMP in TNF--induced lipolysis. Transient transfection with iNOS short hairpin RNA was performed to confirm the involvement of iNOS in TNF--induced lipolysis. Phosphorylation of hormone-sensitive lipase (HSL) was measured by immunoprecipitation and Western blotting. Results showed that short-term TNF- treatment significantly increased lipolysis, iNOS expression, and NO production in a time- and dose-dependent manner. Furthermore, treatment with the NO donor S-nitroso-<I>N</I>-acetylpenicillamine also stimulated lipolysis and HSL phosphorylation in 3T3-L1 adipocytes. Moreover, pretreatment with inhibitors of iNOS and guanylate cyclase, but not an adenylate cyclase inhibitor, abolished TNF--induced lipolysis and HSL phosphorylation. Suppression of TNF--induced iNOS expression using short hairpin RNA significantly reduced TNF--induced lipolysis. In conclusion, <b>s</b>hort-term TNF- treatment induces lipolysis in 3T3-L1 adipocytes by increasing iNOS expression and NO production, which activates the guanylyl cyclase/cGMP-dependent pathway and induces phosphorylation of HSL.</p>
]]></description>
<dc:creator><![CDATA[Lien, C.-C., Au, L.-C., Tsai, Y.-L., Ho, L.-T., Juan, C.-C.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0403</dc:identifier>
<dc:title><![CDATA[Short-Term Regulation of Tumor Necrosis Factor-{alpha}-Induced Lipolysis in 3T3-L1 Adipocytes Is Mediated through the Inducible Nitric Oxide Synthase/Nitric Oxide-Dependent Pathway]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4900</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4892</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4901?rss=1">
<title><![CDATA[Changes in Hypothalamically Mediated Acute-Phase Inflammatory Responses to Lipopolysaccharide in Diet-Induced Obese Rats]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4901?rss=1</link>
<description><![CDATA[
<p>Recent evidence suggests that inflammation may be a common underlying cause of many obesity-associated conditions. To test whether obesity changes the response to inflammation, we investigated its effects on the acute phase of the inflammatory response to an endogenous pathogen, lipopolysaccharide (LPS). Diet-induced obese male Wistar rats exhibited an increased and prolonged fever response to LPS (100 &micro;g/kg) relative to lean rats. LPS-treated obese rats also showed a greater increase in circulating TNF-, IL-6, and IL-1 receptor antagonist within the first 8 h after LPS injection. LPS induced an increase in circulating leptin only in obese rats with no effect in lean rats. Analysis of expression of pyrogenic signaling in the hypothalamus demonstrated that obese rats show a greater increase in IL-1&beta; peaking at 2 h after LPS injection and suppressor of cytokine signaling 3 and IL-6 peaking at the 8-h time point. LPS-treated obese rats showed a significantly higher expression of IL-1 receptor antagonist in white adipose tissue (WAT) than lean rats, and WAT from obese rats incubated in LPS-supplemented medium (100 ng/ml) secreted a significantly higher level of IL-6. Overall, these results suggest that diet-induced obesity induces changes in the inflammatory response rendering the obese rats more responsive to the effects of LPS. These data also support the hypothesis that qualitative changes in WAT associated with obesity may contribute to these effects.</p>
]]></description>
<dc:creator><![CDATA[Pohl, J., Woodside, B., Luheshi, G. N.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0526</dc:identifier>
<dc:title><![CDATA[Changes in Hypothalamically Mediated Acute-Phase Inflammatory Responses to Lipopolysaccharide in Diet-Induced Obese Rats]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4910</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4901</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4911?rss=1">
<title><![CDATA[Central Nesfatin-1 Reduces Dark-Phase Food Intake and Gastric Emptying in Rats: Differential Role of Corticotropin-Releasing Factor2 Receptor]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4911?rss=1</link>
<description><![CDATA[
<p>Nesfatin-1, derived from nucleobindin2, is expressed in the hypothalamus and reported in one study to reduce food intake (FI) in rats. To characterize the central anorexigenic action of nesfatin-1 and whether gastric emptying (GE) is altered, we injected nesfatin-1 into the lateral brain ventricle (intracerebroventricular, icv) or fourth ventricle (4v) in chronically cannulated rats or into the cisterna magna (intracisternal, ic) under short anesthesia and compared with ip injection. Nesfatin-1 (0.05 &micro;g/rat, icv) decreased 2&ndash;3 h and 3&ndash;6 h dark-phase FI by 87 and 45%, respectively, whereas ip administration (2 &micro;g/rat) had no effect. The corticotropin-releasing factor (CRF)<SUB>1</SUB>/CRF<SUB>2</SUB> antagonist astressin-B or the CRF<SUB>2</SUB> antagonist astressin<SUB>2</SUB>-B abolished icv nesfatin-1&rsquo;s anorexigenic action, whereas an astressin<SUB>2</SUB>-B analog, devoid of CRF-receptor binding affinity, did not. Nesfatin-1 icv induced a dose-dependent reduction of GE by 26 and 43% that was not modified by icv astressin<SUB>2</SUB>-B. Nesfatin-1 into the 4v (0.05 &micro;g/rat) or ic (0.5 &micro;g/rat) decreased cumulative dark-phase FI by 29 and 60% at 1 h and by 41 and 37% between 3 and 5 h, respectively. This effect was neither altered by ic astressin<SUB>2</SUB>-B nor associated with changes in GE. Cholecystokinin (ip) induced Fos expression in 43% of nesfatin-1 neurons in the paraventricular hypothalamic nucleus and 24% of those in the nucleus tractus solitarius. These data indicate that nesfatin-1 acts centrally to reduce dark phase FI through CRF<SUB>2</SUB>-receptor-dependent pathways after forebrain injection and CRF<SUB>2</SUB>-receptor-independent pathways after hindbrain injection. Activation of nesfatin-1 neurons by cholecystokinin at sites regulating food intake may suggest a role in gut peptide satiation effect.</p>
]]></description>
<dc:creator><![CDATA[Stengel, A., Goebel, M., Wang, L., Rivier, J., Kobelt, P., Monnikes, H., Lambrecht, N. W. G., Tache, Y.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:54 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0578</dc:identifier>
<dc:title><![CDATA[Central Nesfatin-1 Reduces Dark-Phase Food Intake and Gastric Emptying in Rats: Differential Role of Corticotropin-Releasing Factor2 Receptor]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4919</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4911</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4920?rss=1">
<title><![CDATA[In Vivo Characterization of High Basal Signaling from the Ghrelin Receptor]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4920?rss=1</link>
<description><![CDATA[
<p>The receptor for the orexigenic peptide, ghrelin, is one of the most constitutively active 7TM receptors known, as demonstrated under <I>in vitro</I> conditions. Change in expression of a constitutively active receptor is associated with change in signaling independent of the endogenous ligand. In the following study, we found that the expression of the ghrelin receptor in the hypothalamus was up-regulated approximately 2-fold in rats both during 48-h fasting and by streptozotocin-induced hyperphagia. In a separate experiment, to probe for the effect of the high basal signaling of the ghrelin receptor <I>in vivo</I>, we used intracerebroventricular administration by osmotic pumps of a peptide [D-Arg<sup>1</sup>, D-Phe<sup>5</sup>, D-Trp<sup>7,9</sup>, Leu<sup>11</sup>]-substance P. This peptide selectively displays inverse agonism at the ghrelin receptor as compared with an inactive control peptide with just a single amino acid substitution. Food intake and body weight were significantly decreased in the group of rats treated with the inverse agonist, as compared with the groups treated with the control peptide or the vehicle. In the hypothalamus, the expression of neuropeptide Y and uncoupling protein 2 was decreased by the inverse agonist. In a hypothalamic cell line that endogenously expresses the ghrelin receptor, we observed high basal activity of the cAMP response element binding protein, an important signaling transduction pathway for appetite regulation. The activation was further increased by ghrelin administration and decreased by administration of the inverse agonist. It is suggested that the high constitutive signaling activity is important for the <I>in vivo</I> function of the ghrelin receptor in the control of food intake and body weight.</p>
]]></description>
<dc:creator><![CDATA[Petersen, P. S., Woldbye, D. P. D., Madsen, A. N., Egerod, K. L., Jin, C., Lang, M., Rasmussen, M., Beck-Sickinger, A. G., Holst, B.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2008-1638</dc:identifier>
<dc:title><![CDATA[In Vivo Characterization of High Basal Signaling from the Ghrelin Receptor]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4930</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4920</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4931?rss=1">
<title><![CDATA[Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4931?rss=1</link>
<description><![CDATA[
<p>Fibroblast growth factor 21 (FGF21) is a key metabolic regulator. Expressed primarily in liver and adipose tissue, FGF21 is induced via peroxisome proliferator-activated receptor (PPAR) pathways during states requiring increased fatty acid oxidation including fasting and consumption of a ketogenic diet. To test the hypothesis that FGF21 is a physiological regulator that plays a role in lipid oxidation, we generated mice with targeted disruption of the <I>Fgf21</I> locus (FGF21 knockout). Mice lacking FGF21 had mild weight gain and slightly impaired glucose homeostasis, indicating a role in long-term energy homeostasis. Furthermore, FGF21KO mice tolerated a 24-h fast, indicating that FGF21 is not essential in the early stages of starvation. In contrast to wild-type animals in which feeding KD leads to dramatic weight loss, FGF21KO mice fed KD gained weight, developed hepatosteatosis, and showed marked impairments in ketogenesis and glucose control. This confirms the physiological importance of FGF21 in the adaptation to KD feeding. At a molecular level, these effects were accompanied by lower levels of expression of PGC1 and PGC1&beta; in FGF21KO mice, strongly implicating these key transcriptional regulators in the action of FGF21. Furthermore, within the liver, the maturation of the lipogenic transcription factor sterol regulatory element-binding protein-1c was increased in FGF21KO mice, implicating posttranscriptional events in the maladaptation of FGF21KO mice to KD. These data reinforce the role of FGF21 is a critical regulator of long-term energy balance and metabolism. Mice lacking FGF21 cannot respond appropriately to a ketogenic diet, resulting in an impaired ability to mobilize and utilize lipids.</p>
]]></description>
<dc:creator><![CDATA[Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., Maratos-Flier, E.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0532</dc:identifier>
<dc:title><![CDATA[Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4940</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4931</prism:startingPage>
<prism:section>ENERGY BALANCE-OBESITY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4941?rss=1">
<title><![CDATA[Sex Steroid-Dependent and -Independent Action of Hydroxysteroid (17{beta}) Dehydrogenase 2: Evidence from Transgenic Female Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4941?rss=1</link>
<description><![CDATA[
<p>We have recently generated transgenic (TG) mice overexpressing human hydroxysteroid (17&beta;) dehydrogenase 2 enzyme (HSD17B2TG mice) under the ubiquitous chicken &beta;-actin promoter. As shown in the present study, the HSD17B2TG female mice presented with slower gain of body weight as compared with the wild-type (WT) littermates and suffered from ovarian dysfunction and mammary gland hyperplasia associated with increased expression of multiple pregnancy-associated genes. The macroscopic phenotype observed in the mammary gland was likely to be dependent on the increased progesterone and prolactin secretion, and a normal histological appearance was observed in HSD17B2TG mammary gland transplanted into a WT host. However, a significant suppression of several known estrogen target genes in the HSD17B2TG mammary transplants in WT females was observed, suggesting that HSD17B2 modulates estrogen action <I>in vivo</I>. Interestingly, the growth retardation of HSD17B2TG females was not efficiently rescued in the bi-TG mice expressing both HSD17B2 and HSD17B1 enzymes, and the bi-TG mice presented with certain masculinized phenotypes, including lack of nipples and closed vagina, recently reported for HSD17B1TG females. The present data suggest that HSD17B2 expression affects both sex steroid-independent and steroid-dependent pathways.</p>
]]></description>
<dc:creator><![CDATA[Shen, Z., Saloniemi, T., Ronnblad, A., Jarvensivu, P., Pakarinen, P., Poutanen, M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0670</dc:identifier>
<dc:title><![CDATA[Sex Steroid-Dependent and -Independent Action of Hydroxysteroid (17{beta}) Dehydrogenase 2: Evidence from Transgenic Female Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4949</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4941</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4950?rss=1">
<title><![CDATA[Modulation of Vitamin D Receptor Activity by the Corepressor Hairless: Differential Effects of Hairless Isoforms]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4950?rss=1</link>
<description><![CDATA[
<p>The vitamin D receptor (VDR) and its corepressor Hairless (HR) are thought to regulate key steps in the hair cycle because mutations in VDR or HR cause alopecia in humans and mice. Many mammalian cells express two major HR isoforms due to alternative splicing of exon 17. HR isoform-a encodes an 1189-amino acid protein (full-length HR), and isoform-b encodes an 1134-amino acid protein (HR1072-1126). We demonstrated that both HR isoforms are expressed in primary human keratinocytes and in the human keratinocyte cell line HaCaT. In transfected COS-7 cells, the full-length HR repressed VDR-mediated transactivation. In contrast, HR1072-1126 failed to suppress and even stimulated VDR-mediated transactivation. In coimmunoprecipitation, both HR isoforms interacted with the VDR, but only the full-length HR interacted with histone deacetylase 1 (HDAC1). Alanine mutagenesis of two conserved glutamic acids residues (E1100A/E1101A) encoded by exon 17 completely eliminated HR corepressor activity and interactions with HDAC1. When the two HR isoforms were coexpressed in COS-7 cells, the corepressor activity of the full-length HR was not antagonized by the HR1072-1126 isoform. When transfected into HaCaT cells, the full-length HR inhibited endogenous CYP24A1 basal gene expression as well as 1,25-dihydroxyvitamin D<SUB>3</SUB>-stimulated CYP24A1 expression. HR1072-1126 failed to suppress basal or 1,25-dihydroxyvitamin D<SUB>3</SUB>-stimulated CYP24A1 gene expression. In conclusion, we have demonstrated that both HR isoforms are expressed in keratinocytes and that the HR1072-1126 isoform lacks corepressor activity and is unable to bind HDACs. HR1072-1126 may function as a coactivator in some settings by inhibiting HDAC recruitment to the VDR transcriptional complex.</p>
]]></description>
<dc:creator><![CDATA[Malloy, P. J., Wang, J., Jensen, K., Feldman, D.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0358</dc:identifier>
<dc:title><![CDATA[Modulation of Vitamin D Receptor Activity by the Corepressor Hairless: Differential Effects of Hairless Isoforms]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4957</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4950</prism:startingPage>
<prism:section>GENERAL ENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4958?rss=1">
<title><![CDATA[Characterization of Conserved Tandem Donor Sites and Intronic Motifs Required for Alternative Splicing in Corticosteroid Receptor Genes]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4958?rss=1</link>
<description><![CDATA[
<p>Alternative splicing events from tandem donor sites result in mRNA variants coding for additional amino acids in the DNA binding domain of both the glucocorticoid (GR) and mineralocorticoid (MR) receptors. We now show that expression of both splice variants is extensively conserved in mammalian species, providing strong evidence for their functional significance. An exception to the conservation of the MR tandem splice site (an A at position +5 of the MR+12 donor site in the mouse) was predicted to decrease U1 small nuclear RNA binding. In accord with this prediction, we were unable to detect the MR+12 variant in this species. The one exception to the conservation of the GR tandem splice site, an A at position +3 of the platypus GR donor site that was predicted to enhance binding of U1 snRNA, was unexpectedly associated with decreased expression of the variant from the endogenous gene as well as a minigene. An intronic pyrimidine motif present in both GR and MR genes was found to be critical for usage of the downstream donor site, and overexpression of TIA1/TIAL1 RNA binding proteins, which are known to bind such motifs, led to a marked increase in the proportion of GR and MR+12. These results provide striking evidence for conservation of a complex splicing mechanism that involves processes other than stochastic spliceosome binding and identify a mechanism that would allow regulation of variant expression.</p>
]]></description>
<dc:creator><![CDATA[Rivers, C., Flynn, A., Qian, X., Matthews, L., Lightman, S., Ray, D., Norman, M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0346</dc:identifier>
<dc:title><![CDATA[Characterization of Conserved Tandem Donor Sites and Intronic Motifs Required for Alternative Splicing in Corticosteroid Receptor Genes]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4967</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4958</prism:startingPage>
<prism:section>GLUCOCORTICOIDS-CRH-ACTH-ADRENAL</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4968?rss=1">
<title><![CDATA[Activity of Human Pregnancy Insulin-Like Growth Factor Binding Protein-3: Determination by Reconstituting Recombinant Complexes]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4968?rss=1</link>
<description><![CDATA[
<p>During pregnancy, IGF binding protein-3 (IGFBP-3) is completely proteolyzed to fragments with low affinities for IGFs but appears to transport IGFs normally in high-molecular-mass complexes. We previously reported that synthetic isolated amino- and carboxyl-terminal domains of IGFBP-3 cooperate to bind IGFs, and we investigated whether this is the mechanism whereby proteolyzed IGFBP-3 fragments bind IGFs normally in pregnancy serum. Two fragments of IGFBP-3 have been isolated from pregnancy serum, one with the same N-terminal sequence as intact IGFBP-3 (GASSG) and the other with an N-terminal sequence <sup>160</sup>KVDYE. Recombinant forms of these proteins, IGFBP-3<sup>1-159</sup> and IGFBP-3<sup>160-264</sup>, have been synthesized and characterized, demonstrating that although the fragments individually have greatly reduced affinity for IGF complex formation, when combined they cooperate to form complexes with IGF with or without the acid-labile subunit, inhibit IGF transport across endothelial cell monolayers and inhibit IGF-I-induced IGF type I receptor phosphorylation. It is proposed that proteolysis of IGFBP-3 into two discrete complementary fragments does not significantly increase IGF bioavailability, consistent with previous findings that proteolyzed IGFBP-3 in pregnancy serum is functionally normal and circulates as part of the IGF ternary complexes.</p>
]]></description>
<dc:creator><![CDATA[Yan, X., Payet, L. D., Baxter, R. C., Firth, S. M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0090</dc:identifier>
<dc:title><![CDATA[Activity of Human Pregnancy Insulin-Like Growth Factor Binding Protein-3: Determination by Reconstituting Recombinant Complexes]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4976</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4968</prism:startingPage>
<prism:section>GROWTH FACTORS-CYTOKINES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4977?rss=1">
<title><![CDATA[Colony-Stimulating Factor-1 (CSF-1) Directly Inhibits Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Expression by Osteoblasts]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4977?rss=1</link>
<description><![CDATA[
<p>Colony-stimulating factor-1 (CSF-1), released by osteoblasts, stimulates the proliferation of osteoclast progenitors via the c-fms receptor (CSF-1R) and, in combination with receptor activator of nuclear factor-B ligand (RANKL), leads to the formation of mature osteoclasts. Whether the CSF-1R is expressed by osteoblasts and mediates specific biological effects in osteoblasts has not been explored. Wild-type primary calvaria osteoblasts (OB) were analyzed for CSF-1R expression (RT-PCR and Western blot) and functionality (immunocomplex kinase assay). OB were serum starved for 24 h, and the effect of CSF-1 (0&ndash;100 ng/ml) on OB biological activities was determined at 48 h. In wild-type mouse bone marrow cultures, CSF-1 was tested for its effect on RANKL mRNA and osteoclast formation. Because ROS influence osteoblast RANKL expression, studies analyzed the effect of CSF-1 on reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and Nox1 and Nox4 proteins. Results indicate that OB express CSF-1R mRNA and protein and that CSF-1R could be phosphorylated in the presence of CSF-1. In osteoblasts, CSF-1 decreased RANKL mRNA in a dose- and time-dependent manner. Incubation of bone marrow cultures with CSF-1 resulted in a significant decline in tartrate-resistant acid phosphatase (TRACP) activity and CTR expression. RANKL-decreased expression by CSF-1 was correlated with a decrease of NADPH oxidase activity as well as Nox1 and Nox4 protein levels. These findings provide the first evidence that osteoblasts express CSF-1R and are a target for CSF-1 ligand. CSF-1-mediated inhibition of RANKL expression on osteoblasts may provide an important mechanism for coupling bone formation/resorption and preventing excessive osteoclastogenesis during normal skeletal growth.</p>
]]></description>
<dc:creator><![CDATA[Wittrant, Y., Gorin, Y., Mohan, S., Wagner, B., Abboud-Werner, S. L.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0248</dc:identifier>
<dc:title><![CDATA[Colony-Stimulating Factor-1 (CSF-1) Directly Inhibits Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Expression by Osteoblasts]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4988</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4977</prism:startingPage>
<prism:section>GROWTH FACTORS-CYTOKINES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4989?rss=1">
<title><![CDATA[Phosphatidylinositol 3 Kinase/Akt Signal Relay Cooperates with Smad in Bone Morphogenetic Protein-2-Induced Colony Stimulating Factor-1 (CSF-1) Expression and Osteoclast Differentiation]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4989?rss=1</link>
<description><![CDATA[
<p>Murine spleen cells produce mature osteoclasts when cocultured with osteoblastic cells. Colony-stimulating factor (CSF)-1 is the growth factor required for differentiating the monocyte-macrophage precursor cells into preosteoclasts. Bone morphogenic protein (BMP) signaling in osteoblasts regulates bone mass in mice, suggesting a role of BMP in osteoclastogenesis along with osteoblast activity. The intracellular signal transduction cross talk regulating the osteoblastic production of CSF-1 as a mechanism of BMP-induced osteoclastogenesis is described in this report. We have recently described the involvement of Smad 1/5 in BMP-2-induced CSF-1 expression and osteoclast formation. In this study, using the pharmacological inhibitors and the adenovirus (Ad) vectors expressing dominant-negative (DN) phosphatidylinositol 3 kinase (PI3K), the PI3K-signaling inhibitor, phosphatase and tensin homolog deleted in chromosome 10 (PTEN) or DN Akt kinase in the <I>in vitro</I> coculture assay, we show an essential role of the lipid kinase cascade in BMP-2-mediated multinucleated osteoclast formation and CSF-1 mRNA expression, transcription, and secretion. Inhibition of PI3K/Akt signaling blocked the binding of Smads 1/5 to the CSF-1 BMP-responsive element present in the CSF-1 promoter, resulting in attenuation of Smad-dependent CSF-1 transcription. Furthermore, PI3K inhibition and DN Akt prevented association of the transcriptional coactivator, CREB (cAMP response element binding protein) binding protein (CBP), with Smads 1/5. Together, these data for the first time demonstrate that PI3K-dependent Akt activation regulates BMP-2-induced CSF-1 expression and provides a mechanism for osteoblastic cell-assisted osteoclast differentiation.</p>
]]></description>
<dc:creator><![CDATA[Mandal, C. C., Ghosh Choudhury, G., Ghosh-Choudhury, N.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0026</dc:identifier>
<dc:title><![CDATA[Phosphatidylinositol 3 Kinase/Akt Signal Relay Cooperates with Smad in Bone Morphogenetic Protein-2-Induced Colony Stimulating Factor-1 (CSF-1) Expression and Osteoclast Differentiation]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>4998</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4989</prism:startingPage>
<prism:section>GROWTH FACTORS-CYTOKINES</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/4999?rss=1">
<title><![CDATA[Maternal High-Fat Diet Promotes Body Length Increases and Insulin Insensitivity in Second-Generation Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/4999?rss=1</link>
<description><![CDATA[
<p>Maternal obesity and diet consumption during pregnancy have been linked to offspring adiposity, cardiovascular disease, and impaired glucose metabolism. Furthermore, nutrition during development is clearly linked to somatic growth. However, few studies have examined whether phenotypes derived from maternal high-fat diet exposure can be passed to subsequent generations and by what mechanisms this may occur. Here we report the novel finding of a significant body length increase that persisted across at least two generations of offspring in response to maternal high-fat diet exposure. This phenotype is not attributable to altered intrauterine conditions or maternal feeding behavior because maternal and paternal lineages were able to transmit the effect, supporting a true epigenetic manner of inheritance. We also detected a heritable feature of reduced insulin sensitivity across two generations. Alterations in the GH secretagogue receptor (GHSR), the GHSR transcriptional repressor AF5q31, plasma IGF-I concentrations, and IGF-binding protein-3 (IGFBP3) suggest a contribution of the GH axis. These studies provide evidence that the heritability of body length and glucose homeostasis are modulated by maternal diet across multiple generations, providing a mechanism where length can increase rapidly in concert with caloric availability.</p>
]]></description>
<dc:creator><![CDATA[Dunn, G. A., Bale, T. L.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0500</dc:identifier>
<dc:title><![CDATA[Maternal High-Fat Diet Promotes Body Length Increases and Insulin Insensitivity in Second-Generation Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5009</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>4999</prism:startingPage>
<prism:section>GROWTH HORMONE-SOMATOSTATIN-GRH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5010?rss=1">
<title><![CDATA[Selective Estrogen Receptor Modulators Decrease Reactive Astrogliosis in the Injured Brain: Effects of Aging and Prolonged Depletion of Ovarian Hormones]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5010?rss=1</link>
<description><![CDATA[
<p>After brain injury, astrocytes acquire a reactive phenotype characterized by a series of morphological and molecular modifications, including the expression of the cytoskeletal protein vimentin. Previous studies have shown that estradiol down-regulates reactive astrogliosis. In this study we assessed whether raloxifene and tamoxifen, two selective estrogen receptor modulators, have effects similar to estradiol in astrocytes. We also assessed whether aging and the timing of estrogenic therapy after ovariectomy influence the action of the estrogenic compounds. Four groups of animals were studied: 1) young rats, ovariectomized at 2 months of age; 2) middle-aged rats, ovariectomized at 8 months of age; 3) aged rats, ovariectomized at 18 months of age; and 4) aged rats, ovariectomized at 2 months and sham operated at 18 months of age. Fifteen days after ovariectomy or sham surgery, animals received a stab wound brain injury and the treatment with the estrogenic compounds. The number of vimentin-immunoreactive astrocytes after injury was significantly higher in the hippocampus of aged rats after a long-term ovariectomy compared with aged animals after a short-term ovariectomy and middle-aged rats. In addition, reactive astrocytes were more numerous in the two groups of aged animals than in young animals. Despite these differences, the estrogenic compounds reduced reactive astrogliosis in all animal groups. These findings indicate that estradiol, raloxifene, and tamoxifen are potential candidates for the control of astrogliosis in young and older individuals and after a prolonged depletion of ovarian hormones.</p>
]]></description>
<dc:creator><![CDATA[Barreto, G., Santos-Galindo, M., Diz-Chaves, Y., Pernia, O., Carrero, P., Azcoitia, I., Garcia-Segura, L. M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0352</dc:identifier>
<dc:title><![CDATA[Selective Estrogen Receptor Modulators Decrease Reactive Astrogliosis in the Injured Brain: Effects of Aging and Prolonged Depletion of Ovarian Hormones]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5015</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5010</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5016?rss=1">
<title><![CDATA[The Mammalian Target of Rapamycin as Novel Central Regulator of Puberty Onset via Modulation of Hypothalamic Kiss1 System]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5016?rss=1</link>
<description><![CDATA[
<p>The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that operates as sensor of cellular energy status and effector for its coupling to cell growth and proliferation. At the hypothalamic arcuate nucleus, mTOR signaling has been recently proposed as transducer for leptin effects on energy homeostasis and food intake. However, whether central mTOR also participates in metabolic regulation of fertility remains unexplored. We provide herein evidence for the involvement of mTOR in the control of puberty onset and LH secretion, likely via modulation of hypothalamic expression of Kiss1. Acute activation of mTOR by <scp>l</scp>-leucine stimulated LH secretion in pubertal female rats, whereas chronic <scp>l</scp>-leucine infusion partially rescued the state of hypogonadotropism induced by food restriction. Conversely, blockade of central mTOR signaling by rapamycin caused inhibition of the gonadotropic axis at puberty, with significantly delayed vaginal opening, decreased LH and estradiol levels, and ovarian and uterine atrophy. Inactivation of mTOR also blunted the positive effects of leptin on puberty onset in food-restricted females. Yet the GnRH/LH system retained their ability to respond to ovariectomy and kisspeptin-10 after sustained blockade of mTOR, ruling out the possibility of unspecific disruption of GnRH function by rapamycin. Finally, mTOR inactivation evoked a significant decrease of Kiss1 expression at the hypothalamus, with dramatic suppression of Kiss1 mRNA levels at the arcuate nucleus. Altogether our results unveil the role of central mTOR signaling in the control of puberty onset and gonadotropin secretion, a phenomenon that involves the regulation of Kiss1 and may contribute to the functional coupling between energy balance and gonadal activation and function.</p>
]]></description>
<dc:creator><![CDATA[Roa, J., Garcia-Galiano, D., Varela, L., Sanchez-Garrido, M. A., Pineda, R., Castellano, J. M., Ruiz-Pino, F., Romero, M., Aguilar, E., Lopez, M., Gaytan, F., Dieguez, C., Pinilla, L., Tena-Sempere, M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0096</dc:identifier>
<dc:title><![CDATA[The Mammalian Target of Rapamycin as Novel Central Regulator of Puberty Onset via Modulation of Hypothalamic Kiss1 System]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5026</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5016</prism:startingPage>
<prism:section>NEUROENDOCRINOLOGY</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5027?rss=1">
<title><![CDATA[Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5027?rss=1</link>
<description><![CDATA[
<p>We reported previously that chromogranin A (<I>Chga</I>) knockout (KO) mice are hypertensive and hyperadrenergic. Here we sought to determine the basis of such alterations by probing physiological, biochemical, and pharmacological responses to perturbations of the autonomic nervous system. In the conscious state, KO mice had substantially elevated basal high blood pressure (BP) and heart rate (HR); immobilization stress caused increments in systolic BP and HR in both wild-type (WT) and KO mice, with higher maxima but blunted increments in the KO state. Catestatin (CST; CHGA<SUB>352&ndash;372</SUB>) selectively diminished stress-induced increments in BP and HR in KO mice, implicating CST as an antihypertensive peptide, even in stressful conditions. Heightened plasma catecholamines in KO mice returned to WT level after CST. Stress caused further increments in catecholamines in WT mice but no change in KO mice. KO mice displayed diminished baroreflex sensitivity in response to either phenylephrine or sodium nitroprusside, accounting for exaggerated pressor and depressor responses to these compounds; baroreceptor function was normalized by CST. To probe the relative roles of endogenous/basal sympathetic <I>vs</I>. parasympathetic tone in control of BP and HR, we used the muscarinic-cholinergic antagonist atropine or the &beta;-adrenergic antagonist propranolol; HR and BP responses to each antagonist were exaggerated in KO animals. We conclude that ablation of <I>Chga</I> expression results in global disturbances in autonomic function, both sympathetic and parasympathetic, that can be abrogated (or rescued), at least in part, by replacement of CST. The results point to mechanisms whereby CHGA and its CST fragment act to control cardiovascular homeostasis.</p>
]]></description>
<dc:creator><![CDATA[Gayen, J. R., Gu, Y., O'Connor, D. T., Mahata, S. K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0429</dc:identifier>
<dc:title><![CDATA[Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5035</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5027</prism:startingPage>
<prism:section>RENAL-CARDIAC-VASCULAR</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5036?rss=1">
<title><![CDATA[Convergence of 3',5'-Cyclic Adenosine 5'-Monophosphate/Protein Kinase A and Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling in Corpus Luteum Progesterone Synthesis]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5036?rss=1</link>
<description><![CDATA[
<p>Progesterone secretion by the steroidogenic cells of the corpus luteum (CL) is essential for reproduction. Progesterone synthesis is under the control of LH, but the exact mechanism of this regulation is unknown. It is established that LH stimulates the LH receptor/choriogonadotropin receptor, a G-protein coupled receptor, to increase cAMP and activate cAMP-dependent protein kinase A (PKA). In the present study, we tested the hypothesis that cAMP/PKA-dependent regulation of the Wnt pathway components glycogen synthase kinase (GSK)-3&beta; and &beta;-catenin contributes to LH-dependent steroidogenesis in luteal cells. We observed that LH via a cAMP/PKA-dependent mechanism stimulated the phosphorylation of GSK3&beta; at N-terminal Ser9 causing its inactivation and resulted in the accumulation of &beta;-catenin. Overexpression of N-terminal truncated &beta;-catenin (90 &beta;-catenin), which lacks the phosphorylation sites responsible for its destruction, significantly augmented LH-stimulated progesterone secretion. In contrast, overexpression of a constitutively active mutant of GSK3&beta; (GSK-S9A) reduced &beta;-catenin levels and inhibited LH-stimulated steroidogenesis. Chromatin immunoprecipitation assays demonstrated the association of &beta;-catenin with the proximal promoter of the StAR gene, a gene that expresses the steroidogenic acute regulatory protein, which is a cholesterol transport protein that controls a rate-limiting step in steroidogenesis. Collectively these data suggest that cAMP/PKA regulation of GSK3&beta;/&beta;-catenin signaling may contribute to the acute increase in progesterone production in response to LH.</p>
]]></description>
<dc:creator><![CDATA[Roy, L., McDonald, C. A., Jiang, C., Maroni, D., Zeleznik, A. J., Wyatt, T. A., Hou, X., Davis, J. S.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0771</dc:identifier>
<dc:title><![CDATA[Convergence of 3',5'-Cyclic Adenosine 5'-Monophosphate/Protein Kinase A and Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling in Corpus Luteum Progesterone Synthesis]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5045</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5036</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5046?rss=1">
<title><![CDATA[Colony-Stimulating Factor 2 (CSF-2) Improves Development and Posttransfer Survival of Bovine Embryos Produced in Vitro]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5046?rss=1</link>
<description><![CDATA[
<p>In this study, we tested the role of colony-stimulating factor 2 (CSF2) as one of the regulatory molecules that mediate maternal effects on embryonic development during the preimplantation period. Our objective was to verify effects of CSF2 on blastocyst yield, determine posttransfer survival, and evaluate properties of the blastocyst formed after CSF2 treatment. <I>In vitro</I>, CSF2 increased the percentage of oocytes that became morulae and blastocysts. Blastocysts that were treated with CSF2 tended to have a greater number of inner cell mass cells and had a higher ratio of inner cell mass to trophectoderm cells. There was no effect of CSF2 on the incidence of apoptosis. Treatment with CSF2 from d 5 to 7 after insemination increased embryonic survival as indicated by improved pregnancy rate at d 30&ndash;35 of gestation. Moreover, treatment with CSF2 from either d 1&ndash;7 or 5&ndash;7 after insemination reduced pregnancy loss after d 30&ndash;35. Results indicate that treatment with CSF2 can affect embryonic development and enhance embryo competence for posttransfer survival. The fact that treatment with CSF2 during such a narrow window of development altered embryonic function much later in pregnancy suggests that CSF2 may exert epigenetic effects on the developing embryo that result in persistent changes in function during the embryonic and fetal periods of development.</p>
]]></description>
<dc:creator><![CDATA[Loureiro, B., Bonilla, L., Block, J., Fear, J. M., Bonilla, A. Q. S., Hansen, P. J.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0481</dc:identifier>
<dc:title><![CDATA[Colony-Stimulating Factor 2 (CSF-2) Improves Development and Posttransfer Survival of Bovine Embryos Produced in Vitro]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5054</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5046</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5055?rss=1">
<title><![CDATA[Glucocorticoids Amplify Dibutyl Phthalate-Induced Disruption of Testosterone Production and Male Reproductive Development]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5055?rss=1</link>
<description><![CDATA[
<p>Common male reproductive abnormalities including cryptorchidism, hypospadias, and low sperm counts may comprise a testicular dysgenesis syndrome (TDS), resulting from fetal testis dysfunction during a critical developmental period involving reduced androgen production/action. The recent increase in TDS prevalence suggests environmental/lifestyle factors may be etiologically important. The developing fetus is exposed to multimodal challenges, and we hypothesized that exposure to a combination of factors rather than single agents may be important in the pathogenesis of TDS. We experimentally induced fetal testis dysfunction in rats via treatment of pregnant females daily from embryonic day (e) 13.5 to e21.5 with vehicle, 100 or 500 mg/kg &middot; d dibutyl phthalate (DBP), 0.1 mg/kg &middot; d dexamethasone (Dex), or a combination of DBP + Dex. In adulthood, penile length/normality, testis weight/descent, prostate weight, and plasma testosterone levels were measured plus anogenital distance (AGD) as a measure of androgen action within the masculinization programming window. Intratesticular testosterone and steroidogenic enzyme gene expression were measured in fetal testes at e17.5. High-dose DBP reduced fetal intratesticular testosterone and steroidogenic gene expression; induced mild hypospadias (31%) and cryptorchidism (53%); and reduced penile length, AGD, and testis and prostate weight in adulthood. Dex alone had no effect except to reduce birth weight but amplified the adverse effects of 500 mg/kg &middot; d DBP and exacerbated the effects of 100 mg/kg &middot; d DBP. All adverse effects were highly correlated to AGD, emphasizing the etiological importance of the masculinization programming window. These findings suggest that exposure to common environmental chemicals in combination with, for example, maternal stress, may increase the risk of common male reproductive abnormalities, with implications for human populations.</p>
]]></description>
<dc:creator><![CDATA[Drake, A. J., van den Driesche, S., Scott, H. M., Hutchison, G. R., Seckl, J. R., Sharpe, R. M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0700</dc:identifier>
<dc:title><![CDATA[Glucocorticoids Amplify Dibutyl Phthalate-Induced Disruption of Testosterone Production and Male Reproductive Development]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5064</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5055</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5065?rss=1">
<title><![CDATA[In Pursuit of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor-5 Regulation and Function in the Uterus]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5065?rss=1</link>
<description><![CDATA[
<p>Leucine-rich repeat-containing G protein-coupled receptor (LGR)-5 is a recently identified marker of stem cells in adult intestinal epithelium and hair follicles. Because of this characteristic, we studied the status of <I>Lgr5</I> expression in the mouse uterus under various conditions. <I>Lgr5</I> is highly expressed in the uterine epithelium of immature mice and is dramatically down-regulated after the mice resume estrous cycles. Surprisingly, whereas its expression is up-regulated in uteri of ovariectomized mice, the expression is down-regulated by estrogen and progesterone via their cognate nuclear receptors, estrogen receptor- and progesterone receptor, respectively. Using a mouse endometrial cancer model, we also found that <I>Lgr5</I> is highly expressed in the epithelium during the initial stages of tumorigenesis but is remarkably down-regulated in fully developed tumors. <I>Lgr5</I> is a downstream target of Wnt signaling in the intestine. Genetic evidence shows that either excessive or absence of Wnt signaling dampens <I>Lgr5</I> expression in the uterus. Collectively, our results show that <I>Lgr5</I> expression in the mouse uterine epithelium is unique and dynamically regulated under various physiological and pathological states of the uterus, suggesting that this orphan receptor has important functions in uterine biology. However, identifying definitive uterine function of LGR5 will require further investigation using conditional deletion of uterine <I>Lgr5</I> because systemic deletion of this gene is neonatally lethal.</p>
]]></description>
<dc:creator><![CDATA[Sun, X., Jackson, L., Dey, S. K., Daikoku, T.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0690</dc:identifier>
<dc:title><![CDATA[In Pursuit of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor-5 Regulation and Function in the Uterus]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5073</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5065</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5074?rss=1">
<title><![CDATA[Transcriptional Profiling of the Hormone-Responsive Stages of Spermatogenesis Reveals Cell-, Stage-, and Hormone-Specific Events]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5074?rss=1</link>
<description><![CDATA[
<p>Spermatogenesis occurs within the highly complex seminiferous epithelium. This cyclic process is accompanied by dynamic stage-specific transcriptional changes and is driven by androgens and FSH by mechanisms that are unclear. Here we report the impact of acute androgen and FSH suppression on the transcriptional dynamics of the seminiferous epithelium. We used transcriptional profiling to compare the most hormone-sensitive seminiferous epithelial stages (VII and VIII) from control and hormone-suppressed adult rats, together with publicly available datasets to delineate stage- and cell-specific transcriptional changes. The analyses reveal that, in these stages, there was a hormone-responsive down-regulation of spermatogonial and Sertoli cell transcripts maximally expressed in the earlier spermatogenic stages (I&ndash;VI). Transcripts expressed in Sertoli cells from stage VII and beyond were both up- and down-regulated by hormone suppression, with lysosome function, immune system-related genes, and lipid metabolism predicted to be hormone responsive. Hormone-responsive genes with putative roles in integrin-mediated cell adhesion were also identified. In pachytene spermatocytes, there was an initiation of transcription likely important for the completion of meiosis. A transcriptional switch in round spermatids was observed, from a hormone-responsive down-regulation of transcripts expressed in steps 1&ndash;7 spermatids to a hormone-independent up-regulation of transcripts expressed in steps 8&ndash;11 and likely involved in spermatid differentiation and DNA compaction. This study points to the existence of hormone-responsive global transcriptional repressors in Sertoli cells, spermatogonia, and spermatids and reveals novel and diverse cell-specific responses of the seminiferous epithelium to hormone suppression.</p>
]]></description>
<dc:creator><![CDATA[O'Donnell, L., Pratis, K., Wagenfeld, A., Gottwald, U., Muller, J., Leder, G., McLachlan, R. I., Stanton, P. G.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0755</dc:identifier>
<dc:title><![CDATA[Transcriptional Profiling of the Hormone-Responsive Stages of Spermatogenesis Reveals Cell-, Stage-, and Hormone-Specific Events]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5084</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5074</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5085?rss=1">
<title><![CDATA[Foxl2, a Forkhead Transcription Factor, Modulates Nonclassical Activity of the Estrogen Receptor-{alpha}]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5085?rss=1</link>
<description><![CDATA[
<p>Foxl2 is a forkhead transcription factor required for ovary development and ovarian follicle maturation. In this report, we identified and characterized a functional relationship between Foxl2 expression and estrogen receptor (ER)- signaling. We show that Foxl2 has no effect on classical ER-mediated transcription, which occurs through canonical estrogen response elements. However, Foxl2 suppresses ER signaling through nonclassical tethered transcriptional pathways. Specifically, the selective ER modulator tamoxifen stimulates activator protein-1 (AP1)-dependent transcription via the ER, and this enhancement is blocked by Foxl2. Two lines of evidence suggest that Foxl2 suppression is mediated by physical interactions with ER rather than direct action at AP1 binding sites. First, ER is coimmunoprecipitated with Foxl2. Second, activation of a upstream activating sequence (UAS) reporter by Gal4-cJun in the presence of ER and tamoxifen was blocked by Foxl2, demonstrating suppression in the absence of an AP1 site. Cyclooxygenase-2 (COX2), which is required for ovulation, was identified through expression profiling as a candidate physiological target for nonclassical ER signaling and thus modulation by ER/Foxl2 interactions. This possibility was confirmed by two sets of experiments. COX2 protein levels were induced by ER in the presence of tamoxifen, and protein expression was suppressed by Foxl2. In addition, ER stimulation of the COX2 promoter was repressed by Foxl2. We conclude that ER and Foxl2 interact and that Foxl2 selectively suppresses ER-mediated transcription of AP1-regulated genes. These data provide a potential point of convergence for ER and Foxl2 to regulate ovarian development and function.</p>
]]></description>
<dc:creator><![CDATA[Kim, S.-Y., Weiss, J., Tong, M., Laronda, M. M., Lee, E.-J., Jameson, J. L.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0313</dc:identifier>
<dc:title><![CDATA[Foxl2, a Forkhead Transcription Factor, Modulates Nonclassical Activity of the Estrogen Receptor-{alpha}]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5093</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5085</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5094?rss=1">
<title><![CDATA[Spatiotemporal Coupling of Focal Extracellular Matrix Degradation and Reconstruction in the Menstrual Human Endometrium]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5094?rss=1</link>
<description><![CDATA[
<p>Coupling of focal degradation and renewal of the functional layer of menstrual endometrium is a key event of the female reproductive biology. The precise mechanisms by which the various endometrial cell populations control extracellular matrix (ECM) degradation in the functionalis while preserving the basalis and the respective contribution of basalis and functionalis in endometrium regeneration are still unclear. We therefore compared the transcriptome of stromal and glandular cells isolated by laser capture microdissection from the basalis as well as degraded and preserved areas of the functionalis in menstrual endometria. Data were validated by <I>in situ</I> hybridization. Expression profile of selected genes was further analyzed throughout the menstrual cycle, and their response to ovarian steroids withdrawal was studied in a mouse xenograft model. Immunohistochemistry confirmed the results at the protein level. Algorithms for sample clustering segregated biological samples according to cell type and tissue depth, indicating distinct gene expression profiles. Pairwise comparisons identified the greatest numbers of differentially expressed genes in the lysed functionalis when compared with the basalis. Strikingly, in addition to genes products associated with tissue degradation (matrix metalloproteinase and plasmin systems) and apoptosis, superficial lysed stroma was enriched in gene products associated with ECM biosynthesis (collagens and their processing enzymes). These results support the hypothesis that fragments of the functionalis participate in endometrial regeneration during late menstruation. Moreover, menstrual reflux of lysed fragments overexpressing ECM components and adhesion molecules could easily facilitate implantation of endometriotic lesions.</p>
]]></description>
<dc:creator><![CDATA[Gaide Chevronnay, H. P., Galant, C., Lemoine, P., Courtoy, P. J., Marbaix, E., Henriet, P.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0750</dc:identifier>
<dc:title><![CDATA[Spatiotemporal Coupling of Focal Extracellular Matrix Degradation and Reconstruction in the Menstrual Human Endometrium]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5105</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5094</prism:startingPage>
<prism:section>REPRODUCTION-DEVELOPMENT</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5106?rss=1">
<title><![CDATA[Comparison between Hippocampus-Synthesized and Circulation-Derived Sex Steroids in the Hippocampus]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5106?rss=1</link>
<description><![CDATA[
<p>Estradiol (E2) and other sex steroids play essential roles in the modulation of synaptic plasticity and neuroprotection in the hippocampus. To clarify the mechanisms for these events, it is important to determine the respective role of circulating <I>vs.</I> locally produced sex steroids in the male hippocampus. Liquid chromatography-tandem mass spectrometry in combination with novel derivatization was employed to determine the concentration of sex steroids in adult male rat hippocampus. The hippocampal levels of 17&beta;-E2, testosterone (T), and dihydrotestosterone (DHT) were 8.4, 16.9, and 6.6 n<scp>m</scp>, respectively, and these levels were significantly higher than circulating levels. The hippocampal estrone (E1) level was, in contrast, very low around 0.015 n<scp>m</scp>. After castration to deplete circulating high level T, hippocampal levels of T and DHT decreased considerably to 18 and 3%, respectively, whereas E2 level only slightly decreased to 83%. The strong reduction in hippocampal DHT resulting from castration implies that circulating T may be a main origin of DHT. In combination with results obtained from metabolism analysis of [<sup>3</sup>H]steroids, we suggest that male hippocampal E2 synthesis pathway may be androstenedione -&gt; T -&gt; E2 or dehydroepiandrosterone -&gt; androstenediol -&gt; T -&gt; E2 but not androstenedione -&gt; E1 -&gt; E2.</p>
]]></description>
<dc:creator><![CDATA[Hojo, Y., Higo, S., Ishii, H., Ooishi, Y., Mukai, H., Murakami, G., Kominami, T., Kimoto, T., Honma, S., Poirier, D., Kawato, S.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0305</dc:identifier>
<dc:title><![CDATA[Comparison between Hippocampus-Synthesized and Circulation-Derived Sex Steroids in the Hippocampus]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5112</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5106</prism:startingPage>
<prism:section>TECHNICAL COMMUNICATIONS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5113?rss=1">
<title><![CDATA[The RAPID Method for Blood Processing Yields New Insight in Plasma Concentrations and Molecular Forms of Circulating Gut Peptides]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5113?rss=1</link>
<description><![CDATA[
<p>The correct identification of circulating molecular forms and measurement of peptide levels in blood entails that the endocrine peptide being studied is stable and recovered in good yields during blood processing. However, it is not clear whether this is achieved in studies using standard blood processing. Therefore, we compared peptide concentration and form of 12 <sup>125</sup>I-labeled peptides using the standard procedure (EDTA-blood on ice) and a new method employing Reduced temperatures, Acidification, Protease inhibition, Isotopic exogenous controls, and Dilution (RAPID). During standard processing there was at least 80% loss for calcitonin-gene-related peptide and cholecystokinin-58 (CCK-58) and more than 35% loss for amylin, insulin, peptide YY forms (PYY<SUB>(1&ndash;36)</SUB> and PYY<SUB>(3&ndash;36)</SUB>), and somatostatin-28. In contrast, the RAPID method significantly improved the recovery for 11 of 12 peptides (<I>P</I> &lt; 0.05) and eliminated the breakdown of endocrine peptides occurring after standard processing as reflected in radically changed molecular forms for CCK-58, gastrin-releasing peptide, somatostatin-28, and ghrelin. For endogenous ghrelin, this led to an acyl/total ghrelin ratio of 1:5 instead of 1:19 by the standard method. These results show that the RAPID method enables accurate assessment of circulating gut peptide concentrations and forms such as CCK-58, acylated ghrelin, and somatostatin-28. Therefore, the RAPID method represents an efficacious means to detect circulating variations in peptide concentrations and form relevant to the understanding of physiological function of endocrine peptides.</p>
]]></description>
<dc:creator><![CDATA[Stengel, A., Keire, D., Goebel, M., Evilevitch, L., Wiggins, B., Tache, Y., Reeve, J. R.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:subject><![CDATA[Endocrinology, Endocrinology]]></dc:subject>
<dc:identifier>info:doi/10.1210/en.2009-0697</dc:identifier>
<dc:title><![CDATA[The RAPID Method for Blood Processing Yields New Insight in Plasma Concentrations and Molecular Forms of Circulating Gut Peptides]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5118</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5113</prism:startingPage>
<prism:section>TECHNICAL COMMUNICATIONS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5119?rss=1">
<title><![CDATA[Fingers as a Marker of Prenatal Androgen Exposure]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5119?rss=1</link>
<description><![CDATA[
<p>Interest in biological substrates of sex-related variations in psychological and physiological characteristics has led to a search for biomarkers of prenatal hormone exposure that can be measured postnatally. There has been particular interest in digit ratio, the relative lengths of the second and fourth fingers (2D:4D), but its validity as a measure of prenatal androgen has not been established. We report the strongest evaluation of the value of 2D:4D as a biomarker for early androgen exposure. Individuals with 46,XY karyotype but no effective prenatal androgen exposure due to complete androgen insensitivity syndrome had digit ratios that were feminized: they were higher than those of typical men and similar to those of typical women. Nevertheless, the effect was modest in size, and there was considerable within-group variability and between-group overlap, indicating that digit ratio is not a good marker of individual differences in prenatal androgen exposure.</p>
]]></description>
<dc:creator><![CDATA[Berenbaum, S. A., Bryk, K. K., Nowak, N., Quigley, C. A., Moffat, S.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:subject><![CDATA[Endocrinology, Endocrinology]]></dc:subject>
<dc:identifier>info:doi/10.1210/en.2009-0774</dc:identifier>
<dc:title><![CDATA[Fingers as a Marker of Prenatal Androgen Exposure]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5124</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5119</prism:startingPage>
<prism:section>TECHNICAL COMMUNICATIONS</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5125?rss=1">
<title><![CDATA[Sphingosine Kinase as a Regulator of Calcium Entry through Autocrine Sphingosine 1-Phosphate Signaling in Thyroid FRTL-5 Cells]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5125?rss=1</link>
<description><![CDATA[
<p>Calcium entry is one of the main regulators of intracellular signaling. Here, we have described the importance of sphingosine, sphingosine kinase 1 (SK1), and sphingosine 1-phosphate (S1P) in regulating calcium entry in thyroid FRTL-5 cells. In cells incubated with the phosphatase inhibitor calyculin A, which evokes calcium entry without mobilizing sequestered intracellular calcium, sphingosine inhibited calcium entry in a concentration-dependent manner. Furthermore, inhibiting SK1 or the ATP-binding cassette ABCC1 multidrug transporter attenuated calcium entry. The addition of exogenous S1P restored calcium entry. Neither sphingosine nor inhibition of SK1 attenuated thapsigargin-evoked calcium entry. Blocking S1P receptor 2 or phospholipase C attenuated calcium entry, whereas blocking S1P receptor 3 did not. Overexpression of wild-type SK1, but not SK2, enhanced calyculin-evoked calcium entry compared with mock-transfected cells, whereas calcium entry was decreased in cells transfected with the dominant-negative G82D SK1 mutant. Exogenous S1P restored calcium entry in G82D cells. Our results suggest that the calcium entry pathway is blocked by sphingosine and that activation of SK1 and the production of S1P, through an autocrine mechanism, facilitate calcium entry through activation of S1P receptor 2. This is a novel mechanism by which the sphingosine-S1P rheostat regulates cellular calcium homeostasis.</p>
]]></description>
<dc:creator><![CDATA[Gratschev, D., Lof, C., Heikkila, J., Bjorkbom, A., Sukumaran, P., Hinkkanen, A., Slotte, J. P., Tornquist, K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:55 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0288</dc:identifier>
<dc:title><![CDATA[Sphingosine Kinase as a Regulator of Calcium Entry through Autocrine Sphingosine 1-Phosphate Signaling in Thyroid FRTL-5 Cells]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5134</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5125</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5135?rss=1">
<title><![CDATA[T Helper Type 17 Immune Response Plays an Indispensable Role for Development of Iodine-Induced Autoimmune Thyroiditis in Nonobese Diabetic-H2h4 Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5135?rss=1</link>
<description><![CDATA[
<p>T helper type 1(Th1)/Th2 paradigm has been expanded by discovery of a novel effector T cell (T<SUB>eff</SUB>) subset, Th17 cells, which produce a proinflammatory cytokine IL-17. Th17 cells have recently been shown to play a major role in numerous autoimmune diseases that had previously been thought to be Th1-dominant diseases. We here studied the significance of Th17 cells in iodine-induced autoimmune thyroiditis in nonobese diabetic-H2<sup>h4</sup> mice, a mouse model of Hashimoto&rsquo;s thyroiditis in humans, which spontaneously develop antithyroglobulin autoantibodies and intrathyroidal lymphocyte infiltration when supplied with iodine in the drinking water. We observed increased numbers of Th1 and Th17 cells in spleen and accumulation of both types of T<SUB>eff</SUB> in the thyroid glands of iodine-fed wild-type mice, indicating that Th17 cells as well as Th1 cells constitute thyroid lesions. Furthermore, the incidence and severity of intrathyroidal lymphocyte infiltration, and the titers of antithyroglobulin autoantibodies were markedly reduced in iodine-treated IL-17<sup>&ndash;/&ndash;</sup> mice as compared with wild-type mice. Of interest, IL-17<sup>+/&ndash;</sup> mice showed an intermediate phenotype. Therefore, the present study, together with a previous report demonstrating the importance of Th1, not Th2, immune response for developing thyroiditis using mice deficient for interferon- or IL-4, clearly indicates that both Th1 and Th17 cells are critical T<SUB>eff</SUB> subsets for the pathogenesis of spontaneous autoimmune thyroiditis in nonobese diabetic-H2<sup>h4</sup> mice.</p>
]]></description>
<dc:creator><![CDATA[Horie, I., Abiru, N., Nagayama, Y., Kuriya, G., Saitoh, O., Ichikawa, T., Iwakura, Y., Eguchi, K.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:subject><![CDATA[Endocrinology, Endocrinology]]></dc:subject>
<dc:identifier>info:doi/10.1210/en.2009-0434</dc:identifier>
<dc:title><![CDATA[T Helper Type 17 Immune Response Plays an Indispensable Role for Development of Iodine-Induced Autoimmune Thyroiditis in Nonobese Diabetic-H2h4 Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5142</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5135</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5143?rss=1">
<title><![CDATA[Residues K128, 132, and 134 in the Thyroid Hormone Receptor-{alpha} Are Essential for Receptor Acetylation and Activity]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5143?rss=1</link>
<description><![CDATA[
<p>The thyroid hormone receptor (TR)- is a nuclear receptor that mediates both transrepression and ligand-dependent transactivation. Here we show that TR is posttranslationally modified by acetylation in response to its own ligand (T<SUB>3</SUB>). Acetylation increases binding to DNA. Using mutagenesis, we identified three conserved lysine residues in the carboxi-terminal extension (CTE) of the DNA binding domain that are targets of the cAMP-response element-binding protein acetyltransferase. Substitution of these lysines by arginines in TR decreased ligand binding affinity and precluded ligand-dependent release of corepressors and recruitment of coactivators. The acetylation TR mutant lost the ability to transactivate even at high T<SUB>3</SUB> concentrations and acts as a dominant-negative inhibitor of wild-type TR activity. In addition, whereas native TR interferes with AP-1 function, the mutant is unable to mediate transrepression. Finally, TR suppresses NIH-3T3 fibroblast transformation by the Ras oncogene both in a ligand-dependent and -independent manner, but the CTE mutant is unable to mediate ligand-dependent repression of transformation. These results reveal a key role for the CTE region on acetylation, ligand affinity, transactivation, transrepression, and antitransforming properties of TR.</p>
]]></description>
<dc:creator><![CDATA[Sanchez-Pacheco, A., Martinez-Iglesias, O., Mendez-Pertuz, M., Aranda, A.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0117</dc:identifier>
<dc:title><![CDATA[Residues K128, 132, and 134 in the Thyroid Hormone Receptor-{alpha} Are Essential for Receptor Acetylation and Activity]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5152</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5143</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5153?rss=1">
<title><![CDATA[The Blood-Brain Barrier Thyroxine Transporter Organic Anion-Transporting Polypeptide 1c1 Displays Atypical Transport Kinetics]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5153?rss=1</link>
<description><![CDATA[
<p>Organic anion-transporting polypeptide (Oatp) 1c1 is a high-affinity T<SUB>4</SUB> transporter expressed in brain barrier cells. Oatp1c1 transports a variety of additional ligands including the conjugated sterol estradiol 17&beta;-glucuronide (E<SUB>2</SUB>17&beta;G). Intriguingly, published data suggest that E<SUB>2</SUB>17&beta;G inhibition of Oatp1c1-mediated T<SUB>4</SUB> transport exhibits characteristics suggestive of atypical transport kinetics. To determine whether Oatp1c1 exhibits atypical transport kinetics, we first performed detailed T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G uptake assays using Oatp1c1 stably transfected HEK293 cells and a wide range of T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G concentrations (100 p<scp>m</scp> to 300 n<scp>m</scp> and 27 n<scp>m</scp> to 200 &micro;<scp>m</scp>, respectively). Eadie-Hofstee plots derived from these detailed T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G uptake experiments display a biphasic profile consistent with atypical transport kinetics. These data along with T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G <I>cis</I>-inhibition dose-response measurements revealed shared high- and low-affinity Oatp1c1 binding sites for T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G. T<SUB>4</SUB> and E<SUB>2</SUB>17&beta;G recognized these Oatp1c1 binding sites with opposite preferences. In addition, sterols glucuronidated in the 17 or 21 position, exhibited preferential substrate-dependent inhibition of Oatp1c1 transport, inhibiting Oatp1c1-mediated E<SUB>2</SUB>17&beta;G transport more strongly than T<SUB>4</SUB> transport. Together these data reveal that Oatp1c1-dependent substrate transport is a complex process involving substrate interaction with multiple binding sites and competition for binding with a variety of other substrates. A thorough understanding of atypical Oatp1c1 transport processes and substrate-dependent inhibition will allow better prediction of endo- and xenobiotic interactions with the Oatp transporter.</p>
]]></description>
<dc:creator><![CDATA[Westholm, D. E., Salo, D. R., Viken, K. J., Rumbley, J. N., Anderson, G. W.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0769</dc:identifier>
<dc:title><![CDATA[The Blood-Brain Barrier Thyroxine Transporter Organic Anion-Transporting Polypeptide 1c1 Displays Atypical Transport Kinetics]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5162</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5153</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5163?rss=1">
<title><![CDATA[Evidence for a Homodimeric Structure of Human Monocarboxylate Transporter 8]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5163?rss=1</link>
<description><![CDATA[
<p>The human monocarboxylate transporter 8 (hMCT8) protein mediates transport of thyroid hormone across the plasma membrane. Association of hMCT8 mutations with severe psychomotor retardation and disturbed thyroid hormone levels has established its physiological relevance, but little is still known about the basic properties of hMCT8. In this study we present evidence that hMCT8 does not form heterodimers with the ancillary proteins basigin, embigin, or neuroplastin, unlike other MCTs. In contrast, it is suggested that MCT8 exists as monomer and homodimer in transiently and stably transfected cells. Apparently hMCT8 forms stable dimers because the complex is resistant to denaturing conditions and dithiothreitol. Cotransfection of wild-type hMCT8 with a mutant lacking amino acids 267&ndash;360 resulted in formation of homo-and heterodimers of the variants, indicating that transmembrane domains 4&ndash;6 are not involved in the dimerization process. Furthermore, we explored the structural and functional role of the 10 Cys residues in hMCT8. All possible Cys&gt;Ala mutants did not behave differently from wild-type hMCT8 in protein expression, cross-linking experiments with HgCl<SUB>2</SUB> and transport function. Our findings indicate that individual Cys residues are not important for the function of hMCT8 or suggest that hMCT8 has other yet-undiscovered functions in which cysteines play an essential role.</p>
]]></description>
<dc:creator><![CDATA[Visser, W. E., Philp, N. J., van Dijk, T. B., Klootwijk, W., Friesema, E. C. H., Jansen, J., Beesley, P. W., Ianculescu, A. G., Visser, T. J.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0699</dc:identifier>
<dc:title><![CDATA[Evidence for a Homodimeric Structure of Human Monocarboxylate Transporter 8]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5170</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5163</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5171?rss=1">
<title><![CDATA[Knockdown of the Type 3 Iodothyronine Deiodinase (D3) Interacting Protein Peroxiredoxin 3 Decreases D3-Mediated Deiodination in Intact Cells]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5171?rss=1</link>
<description><![CDATA[
<p>The type 3 iodothyronine deiodinase (D3) is the primary deiodinase that inactivates thyroid hormone. Immunoprecipitation of D3, followed by fluorescent two-dimensional difference gel electrophoresis and mass spectrometry, identified peroxiredoxin 3 (Prx3) as a D3-associated protein. This interaction was confirmed using reverse coimmunoprecipitation, in which pull-down of Prx3 resulted in D3 isolation, and by fluorescence resonance energy transfer between cyan fluorescent protein-D3 and yellow fluorescent protein-Prx3. Prx3 overexpression did not change D3 activity in transfected HEK 293 cells; however, Prx3 knockdown resulted in a 50% decrease in D3-mediated whole-cell deiodination. Notably, D3 activity of cell lysates with dithiothreitol as an exogenous reducing factor and D3 protein levels were not decreased with Prx3 knockdown, indicating that the observed reduction in whole-cell deiodination was not simply due to a decrease in D3 enzyme levels. Prx3 knockdown did not change D3&rsquo;s affinity for T<SUB>3</SUB> because saturation of D3-mediated whole-cell deiodination occurred between 20 and 200 n<scp>m</scp> T<SUB>3</SUB> both with and without Prx3. Furthermore, the decrease in D3 activity in whole cells was not attributable to nonspecific oxidative stress because pretreatment with the antioxidant N-acetyl cysteine did not reverse the effects of Prx3 knockdown. Thioredoxin, the cofactor needed for Prx3 regeneration, supported D3 microsomal activity; however, Prx3 knockdown did not change D3 activity in this system. In conclusion, knockdown of Prx3 decreases D3 activity in whole cells, whereas absolute levels of D3 are unchanged, consistent with Prx3 playing a rate-limiting role in the regeneration of the D3 enzyme.</p>
]]></description>
<dc:creator><![CDATA[Aerts, G., Arrojo e Drigo, R., Van Herck, S. L. J., Sammels, E., Mirebeau-Prunier, D., Gereben, B., Zeold, A., Harney, J. W., Huang, S. A., Mulcahey, M. A., Van der Geyten, S., Van den Bergh, G., Arckens, L., Darras, V. M., Zavacki, A. M.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0702</dc:identifier>
<dc:title><![CDATA[Knockdown of the Type 3 Iodothyronine Deiodinase (D3) Interacting Protein Peroxiredoxin 3 Decreases D3-Mediated Deiodination in Intact Cells]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5180</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5171</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/content/abstract/150/11/5181?rss=1">
<title><![CDATA[Paired Box Gene 8-Peroxisome Proliferator-Activated Receptor-{gamma} Fusion Protein and Loss of Phosphatase and Tensin Homolog Synergistically Cause Thyroid Hyperplasia in Transgenic Mice]]></title>
<link>http://endo.endojournals.org/cgi/content/abstract/150/11/5181?rss=1</link>
<description><![CDATA[
<p>Approximately 35% of follicular thyroid carcinomas and a small fraction of follicular adenomas are associated with a t(2;3)(q13;p25) chromosomal translocation that fuses paired box gene 8 (<I>PAX8</I>) with the peroxisome proliferator-activated receptor- gene (<I>PPARG</I>), resulting in expression of a PAX8-PPAR fusion protein, PPFP. The mechanism by which PPFP contributes to follicular thyroid neoplasia is poorly understood. Therefore, we have created mice with thyroid-specific expression of PPFP. At 1 yr of age, 25% of PPFP mice demonstrate mild thyroid hyperplasia. We bred these mice to mice with thyroid-specific single-allele deletion of the tumor suppressor <I>Pten</I>, denoted ThyPten<sup>+/&ndash;</sup>. In humans, <I>PTEN</I> deletion is associated with follicular adenomas and carcinomas, and in mice, deletion of one <I>Pten</I> allele causes mild thyroid hyperplasia. We found that PPFP synergizes with ThyPten<sup>+/&ndash;</sup> to cause marked thyroid hyperplasia, but carcinomas were not observed. AKT phosphorylation was increased as expected in the ThyPten<sup>+/&ndash;</sup> thyroids, and also was increased in the PPFP thyroids and in human PPFP follicular cancers. Staining for the cell cycle marker Ki-67 was increased in the PPFP, ThyPten<sup>+/&ndash;</sup>, and PPFP;ThyPten<sup>+/&ndash;</sup> thyroids compared with wild-type thyroids. Several genes with increased expression in PPFP cancers also were found to be increased in the thyroids of PPFP mice. This transgenic mouse model of thyroidal PPFP expression exhibits properties similar to those of PPFP thyroid cancers. However, the mice develop thyroid hyperplasia, not carcinoma, suggesting that additional events are required to cause follicular thyroid cancer.</p>
]]></description>
<dc:creator><![CDATA[Diallo-Krou, E., Yu, J., Colby, L. A., Inoki, K., Wilkinson, J. E., Thomas, D. G., Giordano, T. J., Koenig, R. J.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:identifier>info:doi/10.1210/en.2009-0701</dc:identifier>
<dc:title><![CDATA[Paired Box Gene 8-Peroxisome Proliferator-Activated Receptor-{gamma} Fusion Protein and Loss of Phosphatase and Tensin Homolog Synergistically Cause Thyroid Hyperplasia in Transgenic Mice]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5190</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5181</prism:startingPage>
<prism:section>THYROID-TRH-TSH</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/5191?rss=1">
<title><![CDATA[Hypercortisolemia Is Associated with Severity of Bone Loss and Depression in Hypothalamic Amenorrhea and Anorexia Nervosa]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/5191?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Lawson, E. A., Donoho, D., Miller, K. K., Misra, M., Meenaghan, E., Lydecker, J., Wexler, T., Herzog, D. B., Klibanski, A.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:title><![CDATA[Hypercortisolemia Is Associated with Severity of Bone Loss and Depression in Hypothalamic Amenorrhea and Anorexia Nervosa]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5192</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5191</prism:startingPage>
<prism:section>TRANSLATIONAL HIGHLIGHTS FROM JCEM</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/5191-a?rss=1">
<title><![CDATA[Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/5191-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Shields, B. M., Freathy, R. M., Knight, B. A., Hill, A., Weedon, M. N., Frayling, T. M., Hattersley, A. T., Vaidya, B.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:title><![CDATA[Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5191</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5191</prism:startingPage>
<prism:section>TRANSLATIONAL HIGHLIGHTS FROM JCEM</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/5192?rss=1">
<title><![CDATA[The Role of Insulin-Like Growth Factor (IGF) Binding Protein-2 in the Insulin-Mediated Decrease in IGF-I Bioactivity]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/5192?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Arafat, A. M., Weickert, M. O., Frystyk, J., Spranger, J., Schofl, C., Mohlig, M., Pfeiffer, A. F.H.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:title><![CDATA[The Role of Insulin-Like Growth Factor (IGF) Binding Protein-2 in the Insulin-Mediated Decrease in IGF-I Bioactivity]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5192</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5192</prism:startingPage>
<prism:section>TRANSLATIONAL HIGHLIGHTS FROM JCEM</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/5192-a?rss=1">
<title><![CDATA[The Association of Endogenous Sex Hormones, Adiposity, and Insulin Resistance with Incident Diabetes in Postmenopausal Women]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/5192-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Kalyani, R. R., Franco, M., Dobs, A. S., Ouyang, P., Vaidya, D., Bertoni, A., Gapstur, S. M., Golden, S. H.]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:title><![CDATA[The Association of Endogenous Sex Hormones, Adiposity, and Insulin Resistance with Incident Diabetes in Postmenopausal Women]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5192</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5192</prism:startingPage>
<prism:section>TRANSLATIONAL HIGHLIGHTS FROM JCEM</prism:section>
</item>

<item rdf:about="http://endo.endojournals.org/cgi/reprint/150/11/5193?rss=1">
<title><![CDATA[Erratum]]></title>
<link>http://endo.endojournals.org/cgi/reprint/150/11/5193?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Tue, 20 Oct 2009 10:02:56 PDT</dc:date>
<dc:title><![CDATA[Erratum]]></dc:title>
<dc:publisher>Endocrine Society</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>150</prism:volume>
<prism:endingPage>5193</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>5193</prism:startingPage>
<prism:section>ERRATUM</prism:section>
</item>

</rdf:RDF>